Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04104776 · ClinicalTrials.gov registry record · Phase 1
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1 study of Advanced Solid Tumor and Endometrial Cancer, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 275
- Enrollment target
- 20
- Study locations
NCT04104776 is a Phase 1 study of Advanced Solid Tumor and Endometrial Cancer that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 275 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (44% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04104776, a Phase 1 study of Advanced Solid Tumor and Endometrial Cancer, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 275 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Conditions Studied
Interventions
- DRUG Enzalutamide
- DRUG Tulmimetostat
Study Locations (20)
New York
- NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center - New York
- Weill Medical College of Cornell University - New York
- Montefiore Einstein Center for Cancer Care - The Bronx
Other
- Bergonie Institute - Bordeaux
- Oscar Lambret Center - Lille
- Leon Berard Center - Lyon
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan Hospital - Ann Arbor
- South Texas Accelerated Research Therapeutics (Start) - Midwest Location - Grand Rapids
Washington
- Swedish Cancer Institute - Seattle
- Fred Hutchinson Cancer - Seattle
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2019-09-18 |
| Est. Completion | 2030-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04104776
The ClinicalTrials.gov registry entry for NCT04104776 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (44% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.
NCT04104776 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Other, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04104776 about?
NCT04104776 is a clinical study titled "A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas". The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
What is the current status of trial NCT04104776?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 275 participants. The study started on 2019-09-18. Estimated completion is 2030-02-27.
What conditions does trial NCT04104776 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Endometrial Cancer, Diffuse Large B Cell Lymphoma, Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms, Castration-Resistant.
What interventions are being tested in trial NCT04104776?
The interventions under investigation include: Enzalutamide (DRUG), Tulmimetostat (DRUG).
Who is sponsoring clinical trial NCT04104776?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04104776 being conducted?
This trial has 20 study locations across Georgia, Illinois, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.